Three doses of the Pfizer-BioNTech COVID-19 vaccine were roughly 80 percent effective at preventing infections for children ages 6 months to 5 years old, according to trial data Pfizer released Monday.
Nearly 1,700 children received a third vaccine dose at least two months after their second as part of the trial. An analysis of immune responses to the virus in a subset of the children in the study found their vaccine-driven immune response was similar to that of the second vaccine dose among people ages 16-25.
"The study suggests that a low ... dose of our vaccine, carefully selected based on tolerability data, provides young children with a high level of protection against the recent COVID-19 strains," said BioNTech CEO and Co-Founder Dr. Ugur Sahin. That initial data was focused on a two-dose initial vaccination series, according to Pfizer. Following Monday's announcement of a third dose being effective, the two companies plan to submit the latest data to the U.S. Food and Drug Administration this week.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer 3-dose COVID vaccine 80% effective against symptomatic omicron infection for youngest children
Consulte Mais informação »
Pfizer covid shot 80 percent effective in young kids, early data showsThe results, along with other recent developments, signal that the long and frustrating wait for a vaccine for the youngest children, the last group to lack access, could be over within weeks.
Consulte Mais informação »
Pfizer Says Their COVID-19 Vaccine For Kids Under 5 Is 80% Effective Against OmicronPfizer said in preliminary findings in a subset of a clinical trial indicate that 3 doses of the vaccine are 80% effective in preventing symptomatic infection.
Consulte Mais informação »
Three-dose Covid-19 vaccine produces strong immune response in young children, Pfizer and BioNTech sayThree child-size doses of the Pfizer/BioNTech Covid-19 vaccine appeared to be safe and showed a strong immune response in children ages 6 months to 5 years, the companies said Monday. The vaccine makers said they will finish submitting the trial data to the US Food and Drug Administration this week.
Consulte Mais informação »
COVID-19 vaccine for kids under 5: Pfizer says 3 small doses offer strong protectionPfizer says it plans to give the data to U.S. regulators later this week. The 18 million tots under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination.
Consulte Mais informação »
3 doses of COVID vaccine are effective for kids under 5, Pfizer saysThe long-awaited findings bring the vaccine one step closer to a reality for parents of children ages 6 months to 4 years — the only group that remains ineligible for vaccination.
Consulte Mais informação »